Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries has reported that the Glatiramer Acetate Low-Frequency Administration (GALA) study evaluating a new dose of glatiramer acetate injection (GA) met its primary endpoint.
Subscribe to our email newsletter
The Phase III trial evaluated the efficacy, safety and tolerability of 40mg/1ml GA administered subcutaneously three times a week compared to placebo in relapsing-remitting multiple sclerosis (RRMS) patients.
Teva Pharmaceutical Industries Global Branded R&D, senior vice president of clinical research, Serge Stankovic said the results of the study showed the potential of 40mg/1ml glatiramer acetate to offer patients an effective and safe treatment option with Copaxone using a more convenient dosing regimen.
"We remain focused on the continued research and development of products aimed at improving the treatment experience for patients with MS," Stankovic added.
The double-blind placebo-controlled study, which randomized more than 1,400 patients at 155 multinational sites, showed that GA 40mg/1ml reduced disease activity, while maintaining a favorable safety and tolerability profile.
By significantly reducing the annualized relapse rate by 34.4% compared to placebo (p<0.0001), the GA 40mg/1ml met the study’s primary endpoint.
Initial analysis of the data specifies that secondary clinical endpoints were achieved, with the exception of reduction in brain atrophy.